Jentadueto

Primary Use

Jentadueto is indicated for the treatment of type 2 diabetes in adults. It is used as an adjunct to diet and exercise to help lower blood sugar levels. This medication combines two different glucose-lowering drugs into one tablet.

When It Is Prescribed

Healthcare providers may prescribe Jentadueto in the following circumstances:

• When blood sugar levels are not adequately controlled by diet and exercise alone.
• When a patient is already being treated with both linagliptin and metformin as separate tablets.

Limitations of Use

Jentadueto is not appropriate for everyone with blood sugar issues. It should not be used for:

• Type 1 diabetes.
• Diabetic ketoacidosis (increased ketones in the blood or urine).

It is also not known if Jentadueto is safe for use in people who have a history of pancreatitis, as it has not been specifically studied in that population.

How Jentadueto Works

Jentadueto contains two active ingredients, linagliptin and metformin, which target different processes in the body to manage blood glucose (sugar) levels.

Linagliptin

Linagliptin belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by protecting natural hormones in the body called incretins. These hormones play a vital role in blood sugar regulation:

• Increasing insulin: Incretins signal the pancreas to release more insulin, particularly after eating a meal.
• Reducing sugar production: They signal the liver to produce less glucose when it is not needed.

Metformin

Metformin is a biguanide that helps lower blood sugar through three primary actions:

• Liver production: It decreases the amount of glucose that the liver produces and releases into the bloodstream.
• Absorption: It reduces the amount of sugar the intestines absorb from the food you eat.
• Insulin sensitivity: It helps the body's cells become more sensitive to insulin, allowing them to use the sugar already in the blood more effectively.

By combining these two mechanisms, Jentadueto provides a multi-faceted approach to controlling blood sugar throughout the day and after meals.

Common Side Effects

Many people using this medication experience mild side effects. These may include:

• Diarrhea, nausea, or vomiting
• Stomach upset or gas
• Headache
• Sore throat and stuffy or runny nose
• Physical weakness

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider if you experience:

• Pancreatitis: Severe pain in the upper stomach area that may spread to the back, often accompanied by vomiting.
• Heart Failure: Shortness of breath (even while lying down), unusual tiredness, or swelling in the feet, ankles, or legs.
• Severe Joint Pain: Intense or persistent pain in the joints.
• Skin Reactions: Development of blisters or breakdown of the outer layer of skin, known as bullous pemphigoid.
• Low Blood Sugar (Hypoglycemia): Symptoms include dizziness, sweating, confusion, hunger, or shaking. This is more likely if Jentadueto is taken with other diabetes medications like insulin or sulfonylureas.
• Vitamin B12 Deficiency: Long-term use of metformin may lower B12 levels, which can cause anemia or numbness in the hands and feet.

A very rare but life-threatening condition called lactic acidosis can occur due to the metformin in this medication. Seek emergency help for symptoms like unusual muscle pain, trouble breathing, or feeling very cold and dizzy.

Lactic Acidosis

Jentadueto contains metformin, which has a boxed warning for lactic acidosis. This is a rare but serious medical emergency caused by the buildup of metformin in the blood. It can lead to death and must be treated in a hospital. The risk is higher in individuals with kidney impairment, liver disease, or congestive heart failure. Other risk factors include being 65 or older, having surgery, excessive alcohol intake, or undergoing radiological studies with contrast dye.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported in people taking linagliptin, one of the components of Jentadueto. Before starting this medication, it is important to disclose any history of pancreatitis, gallstones, or high triglyceride levels. If persistent, severe abdominal pain occurs, the medication should be stopped and medical attention sought immediately.

Heart Failure

There is an increased risk of heart failure with medications in the DPP-4 inhibitor class, including linagliptin. Healthcare providers typically monitor for signs such as shortness of breath, swelling in the feet or legs, and unusual tiredness. Individuals with existing heart or kidney disease may be at higher risk.

Kidney Function

Jentadueto is not recommended for people with severe kidney disease (an eGFR below 30 mL/min/1.73 m2). Because metformin is cleared by the kidneys, impaired function increases the risk of lactic acidosis. Kidney function is usually tested before starting treatment and at least once a year thereafter.

Other Precautions

• Vitamin B12 Deficiency: Metformin may lower vitamin B12 levels in the blood. Periodic monitoring of B12 levels may be necessary for those on long-term treatment.
• Hypoglycemia: The risk of low blood sugar increases when Jentadueto is used with other diabetes drugs like insulin or sulfonylureas.
• Severe Joint Pain: Some patients taking DPP-4 inhibitors have reported severe and disabling joint pain. Symptoms may appear shortly after starting the drug or after years of use.
• Bullous Pemphigoid: This is a serious skin reaction involving large, fluid-filled blisters. If skin blistering or erosions occur, the medication may need to be discontinued.
• Allergic Reactions: Serious hypersensitivity reactions, such as anaphylaxis or angioedema, have occurred. These typically happen within the first three months of starting treatment.

Pregnancy

There is limited information regarding the safety of Jentadueto in pregnant women. While animal studies for linagliptin did not show evidence of harm to the fetus at clinical doses, the effects in humans are not fully established. Poorly controlled diabetes during pregnancy increases the risk of complications for both the mother and the baby, including birth defects, stillbirth, and high blood pressure.

Metformin, one of the components of Jentadueto, may cause some premenopausal women who do not have regular periods to begin ovulating again. This can increase the risk of an unintended pregnancy. If you are planning to become pregnant or find out you are pregnant while taking this medication, contact your healthcare provider immediately to discuss your treatment plan.

Breastfeeding

It is not known if linagliptin passes into human breast milk. However, metformin is known to pass into breast milk in small amounts. Because of the potential risk of low blood sugar or other side effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the medication, taking into account the importance of the drug to the mother's health.

Healthcare providers generally recommend discussing the risks and benefits of breastfeeding while using Jentadueto to determine the safest approach for the infant.

Dosage Forms

Jentadueto is supplied as a film-coated tablet intended for oral administration. It is a fixed-dose combination product that contains two active ingredients within a single tablet.

The tablets are typically identified by specific colors and debossed markings on their surface to distinguish between the different available versions of the medication.

FDA Approval and Indications

Jentadueto (linagliptin and metformin hydrochloride) was approved by the U.S. Food and Drug Administration (FDA) to help manage blood glucose levels in adults with type 2 diabetes. It is intended to be used in combination with diet and exercise. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Boxed Warning

The FDA requires a Boxed Warning for Jentadueto due to the risk of lactic acidosis. This is a rare but potentially fatal metabolic complication that can occur if metformin builds up in the blood. Risk factors for this condition include:

• Kidney impairment
• Dehydration
• Excessive alcohol intake
• Hepatic (liver) impairment
• Congestive heart failure
• Advanced age (65 years or older)

Regulatory Updates and Safety Communications

The FDA has issued updates regarding the use of metformin-containing products in patients with kidney disease. Recommendations for use are based on the estimated glomerular filtration rate (eGFR) rather than blood creatinine levels alone. Jentadueto is contraindicated in patients with severe renal impairment, defined as an eGFR below 30 mL/min/1.73 m².

Additionally, the FDA has monitored potential safety signals for the class of drugs known as DPP-4 inhibitors, which includes linagliptin. These signals include the risk of bullous pemphigoid, a skin condition characterized by large, fluid-filled blisters that requires medical attention.

Brand-Name Pricing

Jentadueto is a brand-name combination medication. Because it contains linagliptin, which is a brand-name drug, the cost is typically higher than that of older, generic diabetes treatments. While metformin is available as an inexpensive generic, the combination of these two drugs into a single tablet is currently only available as a brand-name product.

Insurance and Out-of-Pocket Costs

The final price you pay depends on your insurance plan's formulary and your specific coverage level. Most plans cover Jentadueto, but it may be placed in a higher cost-sharing tier, which can result in a higher co-pay. For individuals without insurance, the retail price can vary significantly between different pharmacies.

Formulation Options

Jentadueto is available in both immediate-release and extended-release (Jentadueto XR) forms. The cost may vary depending on which formulation and strength are prescribed by your healthcare provider. It is recommended to check with your insurance provider or pharmacist to determine the specific out-of-pocket costs for your prescription.